Comparison of KONAR-multifunctional occluder and Amplatzer occluders in transcatheter closure of patent arterial ducts and ventricular septal defects.

BACKGROUND

Transcatheter closure of patent ductus arteriosus (PDA) and ventricular septal defect (VSD) is performed using various occluder devices.

OBJECTIVE

We aim to compare the use of KONAR-Multifunctional Occluder (KONAR-MFO) and Amplatzer occluders (ADO-I, ADO-II) for closure of PDAs and VSDs.

METHODS

This is a retrospective study on patients who underwent transcatheter PDA or VSD closure between June 2023 and October 2025. Patients were categorized according to the occlusion device and the underlying defect. Data were analysed comprehensively.

RESULTS

The study included 173 patients; 116 (67.1%) and 57 (32.9%) underwent PDA and VSD closure, respectively, using 99 ADO-I, 53 KONAR-MFO, and 21 ADO-II devices. The KONAR-MFO was used in smaller, younger patients, and the ADO-I in heavier, older patients (p < 0.05). The ADO-I was used for PDA type-A (40.4%), type-E (12.1%), type-C and D (9.1% for each), as well as perimembranous and muscular VSDs (13.1% each). The KONAR-MFO was used for peri-membranous VSDs (47.2%), Gerbode-type VSDs (5.7%), and PDA type-B (14.1%). The ADO-II was employed for PDA type-E (57.1%) and type-C (42.9%), without use in VSDs. The KONAR-MFO and ADO-II devices showed the shortest procedural and fluoroscopy times with the lowest contrast use, owing to single-access deployment without arteriovenous loop formation. Freedom from all types of complications was 73.9%, 71.1%, and 66.7% for KONAR-MFO, ADO-I, and ADO-II, respectively. In ADO-I, residual shunt, device embolization, and complete heart block occurred in 2.0% each. In KONAR-MFO, left pulmonary artery (LPA) stenosis and mild aortic regurgitation were observed in 3.8% each, while residual shunt and device embolization were observed in 1.9%. ADO-II was associated with the highest residual shunt and device embolization, both occurring at 9.5%.

CONCLUSIONS

ADO-I was used to close PDA and VSD, with longer procedural times. KONAR-MFO offered useful applications across complex VSDs with safety profiles in smaller, younger patients. ADO-II was preferred for tubular and elongated PDAs.